Inducible nitric oxide synthase as a possible target in hypertension

Current Drug Targets

Volumn 15, Issue 2, 2014, Pages 164-174

  Oliveira Paula, Gustavo H ^a   Lacchini, Riccardo ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endothelial dysfunction; Hypertension; Inducible nitric oxide synthase; Inducible nitric oxide synthase inhibition; Nitric oxide

Indexed keywords

AMINOGUANIDINE; AMLODIPINE; ARGINASE; ARGININE; CARVEDILOL; COPTIS CHINENSIS EXTRACT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIMASARTAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LACIDIPINE; N [3 (AMINOMETHYL) BENZYL] ACETAMIDINE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NEBIVOLOL; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXYNITRITE; PROANTHOCYANIDIN; PYRROLIDINE DITHIOCARBAMATE; QUERCETIN; QUINAPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG; VALSARTAN;

ATHEROSCLEROSIS; BIOAVAILABILITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; ENZYME INDUCTION; ENZYME INHIBITION; EXPERIMENTAL HYPERTENSION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LIPID PEROXIDATION; MULTIPLE ORGAN FAILURE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGINASE; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PEROXYNITROUS ACID; SUPEROXIDES;

EID: 84892950455     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113146660227     Document Type: Review

References (157)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
3. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
5. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
6. Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 1997; 22: 477-81.
7. Rodriguez-Iturbe B, Zhan CD, Quiroz Y, Sindhu RK, Vaziri ND. Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 2003; 41: 341-6.
8. Watson T, Goon PK, Lip GY. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxidants & redox signaling 2008; 10: 1079-88.
9. Castro MM, Rizzi E, Rodrigues GJ, et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46: 1298-307.
10. Castro MM, Rizzi E, Ceron CS, et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 2012; 26: 162-8.
11. Chou TC, Yen MH, Li CY, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998; 31: 643-8.
12. Hallemeesch MM, Janssen BJ, de Jonge WJ, Soeters PB, Lamers WH, Deutz NE. NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged mice. Am J Physiol Endocrinol Metab 2003; 285: E871-5.
13. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999; 43: 650-7.
14. Charles IG, Palmer RM, Hickery MS, et al. Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci USA 1993; 90: 11419-23.
15. Hausel P, Latado H, Courjault-Gautier F, Felley-Bosco E. Srcmediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase. Oncogene 2006; 25: 198-206.
16. Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 2000; 86: 319-25.
17. Hong Y, Suzuki S, Yatoh S, et al. Effect of hypoxia on nitric oxide production and its synthase gene expression in rat smooth muscle cells. Biochem Biophys Res Commun 2000; 268: 329-32.
18. Lane C, Knight D, Burgess S, et al. Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax 2004; 59: 757-60.
19. Zulueta JJ, Sawhney R, Kayyali U, et al. Modulation of inducible nitric oxide synthase by hypoxia in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 2002; 26: 22-30.
20. Kleinert H, Schwarz PM, Forstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem 2003; 384: 1343-64.
21. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010; 23: 75-93.
22. Delgado M, Ganea D. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 2000; 165: 3051-7.
23. Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJ. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem 1997; 272: 1226-30.
24. De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA. Dexamethasone suppresses iNOS gene expression by upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol 1997; 273: G1290-6.
25. Hong HJ, Loh SH, Yen MH. Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol 2000; 131: 631-7.
26. Paixao J, Dinis TC, Almeida LM. Malvidin-3-glucoside protects endothelial cells up-regulating endothelial NO synthase and inhibiting peroxynitrite-induced NF-kB activation. Chem Biol Interact 2012; 199: 192-200.
27. Yoon EK, Kim HK, Cui S, Kim YH, Lee SH. Soybean glyceollins mitigate inducible nitric oxide synthase and cyclooxygenase-2 expression levels via suppression of the NF-kappaB signaling pathway in RAW 264. 7 cells. Int J Mol Med 2012; 29: 711-7.
28. Mukaida N, Morita M, Ishikawa Y, et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994; 269: 13289-95.
29. Jeon YJ, Han SH, Lee YW, Yea SS, Yang KH. Inhibition of NFkappa B/Rel nuclear translocation by dexamethasone: mechanism for the inhibition of iNOS gene expression. Biochem Mol Biol Int 1998; 45: 435-41.
30. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 2002; 367: 97-105.
31. Saura M, Zaragoza C, Diaz-Cazorla M, et al. Involvement of transcriptional mechanisms in the inhibition of NOS2 expression by dexamethasone in rat mesangial cells. Kidney Int 1998; 53: 38-49.
32. Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, et al. Complex contribution of the 3'-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem 2000; 275: 26040-9.
33. Eberhardt W, Doller A, Akool el S, Pfeilschifter J. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther 2007; 114: 56-73.
34. Chen CY, Gherzi R, Ong SE, et al. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001; 107: 451-64.
35. Fechir M, Linker K, Pautz A, et al. Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene. Mol Pharmacol 2005; 67: 2148-61.
36. Linker K, Pautz A, Fechir M, Hubrich T, Greeve J, Kleinert H. Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR. Nucleic Acids Res 2005; 33: 4813-27.
37. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 2000; 57: 68-74.
38. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 2007; 137: 1616S-20S.
39. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000; 275: 715-9.
40. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 1995; 50: 1321-32.
41. Tzeng E, Billiar TR, Robbins PD, Loftus M, Stuehr DJ. Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci USA. 1995; 92: 11771-5.
42. Muhl H, Pfeilschifter J. Tetrahydrobiopterin is a limiting factor of nitric oxide generation in interleukin 1 beta-stimulated rat glomerular mesangial cells. Kidney Int 1994; 46: 1302-6.
43. Wang SS, Davis S, Cerhan JR, et al. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis 2006; 27: 1828-34.
44. de OSMT, Goncalves FM, Martins-Oliveira A, et al. Inducible nitric oxide synthase haplotype associated with migraine and aura. Mol Cell Biochem 2012; 364: 303-8.
45. Amaral LM, Palei AC, Sandrim VC, et al. Maternal iNOS genetic polymorphisms and hypertensive disorders of pregnancy. J Hum Hypertens 2012; 26: 547-52.
46. Oliveira-Paula GH, Lacchini R, Coeli-Lacchini FB, Junior HM, Tanus-Santos JE. Inducible nitric oxide synthase haplotype associated with hypertension and responsiveness to antihypertensive drug therapy. Gene 2013; 515: 391-5.
47. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87-104.
48. Stoclet JC, Muller B, Gyorgy K, Andriantsiothaina R, Kleschyov AL. The inducible nitric oxide synthase in vascular and cardiac tissue. Eur J Pharmacol 1999; 375: 139-55.
49. Dias-Junior CA, Neto-Neves EM, Montenegro MF, Tanus-Santos JE. Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 2010; 23: 284-8.
50. Stathopulos PB, Lu X, Shen J, Scott JA, et al. Increased L-arginine uptake and inducible nitric oxide synthase activity in aortas of rats with heart failure. Am J Physiol Heart Circ Physiol 2001; 280: H859-67.
51. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1087-94.
52. Ferreiro CR, Chagas AC, Carvalho MH, et al. Expression of inducible nitric oxide synthase is increased in patients with heart failure due to ischemic disease. Braz J Med Biol Res 2004; 37: 1313-20.
53. Vanderheyden M, Bartunek J, Knaapen M, Kockx M, De Bruyne B, Goethals M. Hemodynamic effects of inducible nitric oxide synthase and nitrotyrosine generation in heart failure. J Heart Lung Transplant. 2004; 23: 723-8.
54. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res. 2007; 100: 1089-98.
55. Liu YH, Carretero OA, Cingolani OH, et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2005; 289: H2616-23.
56. Feng Q, Lu X, Jones DL, Shen J, Arnold JM. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001; 104: 700-4.
57. Ohishi M, Dusting GJ, Fennessy PA, Mendelsohn FA, Li XC, Zhuo JL. Increased expression and co-localization of ACE, angiotensin II AT(1) receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries. Int J Physiol Pathophysiol Pharmacol 2010; 2: 111-24.
58. Detmers PA, Hernandez M, Mudgett J, et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 2000; 165: 3430-5.
59. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001; 103: 3099-104.
60. Behr-Roussel D, Rupin A, Simonet S, et al. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor Niminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation 2000; 102: 1033-8.
61. Hayashi T, Matsui-Hirai H, Fukatsu A, et al. Selective iNOS inhibitor, ONO1714 successfully retards the development of highcholesterol diet induced atherosclerosis by novel mechanism. Atherosclerosis 2006; 187: 316-24.
62. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-81.
63. Manning RD, Jr., Hu L, Mizelle HL, Montani JP, Norton MW. Cardiovascular responses to long-term blockade of nitric oxide synthesis. Hypertension 1993; 22: 40-8.
64. Sander M, Hansen J, Victor RG. The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N(omega)-nitro-L-arginine methyl ester. Hypertension 1997; 30: 64-70.
65. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens 1993; 15: 527-37.
66. Ghosh M, Wang HD, McNeill JR. Role of oxidative stress and nitric oxide in regulation of spontaneous tone in aorta of DOCAsalt hypertensive rats. Br J Pharmacol 2004; 141: 562-73.
67. Kumar U, Shin Y, Wersinger C, Patel Y, Sidhu A. Diminished expression of constitutive nitric oxide synthases in the kidney of spontaneously hypertensive rat. Clin Exp Hypertens 2003; 25: 271-82.
68. Moreau C, Lariviere R, Kingma I, Grose JH, Lebel M. Chronic nitric oxide inhibition aggravates hypertension in erythropoietintreated renal failure rats. Clin Exp Hypertens 2000; 22: 663-74.
69. Takahashi H, Hara K, Komiyama Y, Masuda M, Murakami T, Nishimura M, et al. Mechanism of hypertension induced by chronic inhibition of nitric oxide in rats. Hypertens Res 1995; 18: 319-24.
70. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005; 289: R913-35.
71. Hirafuji M, Tsunoda M, Machida T, et al. Reduced expressions of inducible nitric oxide synthase and cyclooxygenase-2 in vascular smooth muscle cells of stroke-prone spontaneously hypertensive rats. Life Sci 2002; 70: 917-26.
72. Alvarez Y, Briones AM, Hernanz R, Perez-Giron JV, Alonso MJ, Salaices M. Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats. Br J Pharmacol 2008; 153: 926-35.
73. Cau SB, Guimaraes DA, Rizzi E, et al. Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension. Br J Pharmacol 2011; 164: 372-81.
74. de Oliveira-Sales EB, Nishi EE, Boim MA, Dolnikoff MS, Bergamaschi CT, Campos RR. Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model. Am J Hypertens 2010; 23: 708-15.
75. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001; 38: 1044-8.
76. Horinaka S, Kobayashi N, Mori Y, Yagi H, Onoda M, Matsuoka H. Expression of inducible nitric oxide synthase, left ventricular function and remodeling in Dahl salt-sensitive hypertensive rats. Int J Cardiol 2003; 91: 25-35.
77. Kimura Y, Hirooka Y, Kishi T, Ito K, Sagara Y, Sunagawa K. Role of inducible nitric oxide synthase in rostral ventrolateral medulla in blood pressure regulation in spontaneously hypertensive rats. Clin Exp Hypertens 2009; 31: 281-6.
78. Kimura Y, Hirooka Y, Sagara Y, et al. Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. Circ Res 2005; 96: 252-60.
79. Kumar U, Chen J, Sapoznikhov V, Canteros G, White BH, Sidhu A. Overexpression of inducible nitric oxide synthase in the kidney of the spontaneously hypertensive rat. Clin Exp Hypertens 2005; 27: 17-31.
80. Ma XL, Gao F, Nelson AH, et al. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001; 298: 879-85.
81. Cuzzocrea S, Mazzon E, Dugo L, Di Paola R, Caputi AP, Salvemini D. Superoxide: a key player in hypertension. FASEB J 2004; 18: 94-101.
82. Linz W, Itter G, Dobrucki LW, Malinski T, Wiemer G. Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction. J Renin Angiotensin Aldosterone Syst 2003; 4: 180-5.
83. Suzuki A, Yamamoto N, Jokura H, et al. Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J Hypertens 2006; 24: 1065-73.
84. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NFkappaB signaling. Cell Res 2011; 21: 103-15.
85. Escobales N, Crespo MJ. Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol 2005; 3: 231-46.
86. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114.
87. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71: 247-58.
88. Wolin MS, Ahmad M, Gupte SA. Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. Am J Physiol Lung Cell Mol Physiol 2005; 289: L159-73.
89. Wolin MS, Ahmad M, Gupte SA. The sources of oxidative stress in the vessel wall. Kidney Int 2005; 67: 1659-61.
90. Yan C, Huang A, Wu Z, et al. Increased superoxide leads to decreased flow-induced dilation in resistance arteries of Mn-SODdeficient mice. Am J Physiol Heart Circ Physiol 2005; 288: H2225-31.
91. Cai H, McNally JS, Weber M, Harrison DG. Oscillatory shear stress upregulation of endothelial nitric oxide synthase requires intracellular hydrogen peroxide and CaMKII. J Mol Cell Cardiol 2004; 37: 121-5.
92. Queisser N, Schupp N. Aldosterone, oxidative stress, and NFkappaB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol Med 2012; 53: 314-27.
93. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004; 75: 639-53.
94. Fu L, Zhao Y, Lu J, et al. Functional single nucleotide polymorphism-1026C/A of inducible nitric oxide synthase gene with increased YY1-binding affinity is associated with hypertension in a Chinese Han population. J Hypertens 2009; 27(5): 991-1000.
95. Li W, Liu H, Fu L, Li D, Zhao Y. Identification of Yin Yang 1-interacting partners at-1026C/A in the human iNOS promoter. Arch Biochem Biophys 2010; 498: 119-26.
96. Herce-Pagliai C, Kotecha S, Shuker DE. Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Nitric Oxide 1998; 2: 324-36.
97. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 2003; 140-141: 113-24.
98. Salvemini D, Cuzzocrea S. Superoxide, superoxide dismutase and ischemic injury. Curr Opin Investig Drugs 2002; 3: 886-95.
99. Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 2005; 26: 302-10.
100. Michell DL, Andrews KL, Chin-Dusting JP. Endothelial dysfunction in hypertension: the role of arginase. Front Biosci (Schol Ed) 2011; 3: 946-60.
101. Cardillo C, Panza JA. Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension. Vasc Med 1998; 3: 138-44.
102. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 2012; 59: 367-74.
103. Lalu MM, Wang W, Schulz R. Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Fail Rev 2002; 7: 359-69.
104. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitriteinduced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001; 276: 29596-602.
105. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012; 413: 656-62.
106. Kim JH, Bugaj LJ, Oh YJ, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol 2009; 107: 1249-57.
107. Di Costanzo L, Sabio G, Mora A, et al. Crystal structure of human arginase I at 1. 29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci USA 2005; 102: 13058-63.
108. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 1995; 57: 707-36.
109. Dunn J, Gutbrod S, Webb A, Pak A, Jandu SK, Bhunia A, et al. Snitrosation of arginase 1 requires direct interaction with inducible nitric oxide synthase. Mol Cell Biochem. 2011; 355: 83-9.
110. Santhanam L, Lim HK, Miriel V, et al. Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 2007; 101: 692-702.
111. Bagnost T, Ma L, da Silva RF, et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 2010; 87: 569-77.
112. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 2005; 23: 971-8.
113. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004; 44: 935-43.
114. Sun Y, Carretero OA, Xu J, et al. Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate-salt hypertension. Hypertension 2005; 46: 1355-61.
115. Sun Y, Carretero OA, Xu J, Rhaleb NE, Yang JJ, Pagano PJ, et al. Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension. Hypertension 2009; 53: 49-56.
116. Dias FA, Urboniene D, Yuzhakova MA, et al. Ablation of iNOS delays cardiac contractile dysfunction in chronic hypertension. Front Biosci (Elite Ed) 2010; 2: 312-24.
117. Virdis A, Ghiadoni L, Versari D, Giannarelli C, Salvetti A, Taddei S. Endothelial function assessment in complicated hypertension. Curr Pharm Des 2008; 14: 1761-70.
118. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endotheliumdependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-74.
119. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-9.
120. Armas-Padilla MC, Armas-Hernandez MJ, Sosa-Canache B, et al. Nitric oxide and malondialdehyde in human hypertension. Am J Ther 2007; 14: 172-6.
121. Vyzantiadis T, Karagiannis A, Douma S, Harsoulis P, Vyzantiadis A, Zamboulis C. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin Exp Hypertens 2006; 28: 603-9.
122. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
123. Smith CJ, Santhanam L, Bruning RS, Stanhewicz A, Berkowitz DE, Holowatz LA. Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans. Hypertension 2011; 58: 935-42.
124. Escames G, Khaldy H, Leon J, Gonzalez L, Acuna-Castroviejo D. Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. J Hypertens 2004; 22: 629-35.
125. Glenn CL, Wang WY, Morris BJ. Different frequencies of inducible nitric oxide synthase genotypes in older hypertensives. Hypertension 1999; 33: 927-32.
126. Yagil Y, Yagil C. Candidate genes, association studies and haplotype analysis in the search for the genetic basis of hypertension. J Hypertens 2004; 22: 1255-8.
127. Tinker AC, Wallace AV. Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr Top Med Chem 2006; 6: 77-92.
128. Mukai Y, Sato S. Polyphenol-containing azuki bean (Vigna angularis) seed coats attenuate vascular oxidative stress and inflammation in spontaneously hypertensive rats. J Nutr Biochem 2011; 22: 16-21.
129. Sharma B, Singh N. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, convalesce behavior and biochemistry of hypertension induced vascular dementia in rats. Pharmacol Biochem Behav 2013; 103: 821-30.
130. Dias-Junior CA, Sertorio JT, Tanus-Santos JE. Aminoguanidine produces beneficial haemodynamic effects in a canine model of acute pulmonary thromboembolism. Acta Physiol (Oxf) 2007; 191: 189-96.
131. Cheng PY, Chen JJ, Yen MH. The expression of heme oxygenase-1 and inducible nitric oxide synthase in aorta during the development of hypertension in spontaneously hypertensive rats. Am J Hypertens 2004; 17: 1127-34.
132. Huang CF, Hsu CN, Chien SJ, Lin YJ, Huang LT, Tain YL. Aminoguanidine attenuates hypertension, whereas 7-nitroindazole exacerbates kidney damage in spontaneously hypertensive rats: the role of nitric oxide. Eur J Pharmacol 2013; 699: 233-40.
133. Mukohda M, Okada M, Hara Y, Yamawaki H. Methylglyoxal accumulation in arterial walls causes vascular contractile dysfunction in spontaneously hypertensive rats. J Pharmacol Sci 2012; 120: 26-35.
134. Chan V, Hoey A, Brown L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol 2006; 148: 902-8.
135. Wang X, Chang T, Jiang B, Desai K, Wu L. Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal. Am J Hypertens 2007; 20: 629-36.
136. Pechanova O, Dobesova Z, Cejka J, Kunes J, Zicha J. Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase. J Hypertens 2004; 22: 167-73.
137. Tan DY, Meng S, Cason GW, Manning RD, Jr. Mechanisms of salt-sensitive hypertension: role of inducible nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2000; 279: R2297-303.
138. Tian N, Gannon AW, Khalil RA, Manning RD, Jr. Mechanisms of salt-sensitive hypertension: role of renal medullary inducible nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R372-9.
139. Lopez-Belmonte J, Whittle BJ. Aminoguanidine-provoked leukocyte adherence to rat mesenteric venules: role of constitutive nitric oxide synthase inhibition. Br J Pharmacol 1995; 116: 2710-4.
140. Ohrui T, Yamauchi K, Sekizawa K, Ohkawara Y, Maeyama K, Sasaki M, et al. Histamine N-methyltransferase controls the contractile response of guinea pig trachea to histamine. J Pharmacol Exp Ther 1992; 261: 1268-72.
141. Rudd MA, Trolliet M, Hope S, Scribner AW, Daumerie G, Toolan G, et al. Salt-induced hypertension in Dahl salt-resistant and saltsensitive rats with NOS II inhibition. Am J Physiol 1999; 277: H732-9.
142. Amaral LM, Pinheiro LC, Guimaraes DA, Palei ACT, Sertório JT, Portella RL, et al. Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental preeclampsia. J Cell Mol Med 2013; 17(10): 1300-7.
143. Tapia E, Sanchez-Gonzalez DJ, Medina-Campos ON, Soto V, Avila-Casado C, Martinez-Martinez CM, et al. Treatment with pyrrolidine dithiocarbamate improves proteinuria, oxidative stress, and glomerular hypertension in overload proteinuria. Am J Physiol Renal Physiol 2008; 295: F1431-9.
144. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2002; 2: 3.
145. Fu R, Chen Z, Wang Q, Guo Q, Xu J, Wu X. XJP-1, a novel ACEI, with anti-inflammatory properties in HUVECs. Atherosclerosis 2011; 219: 40-8.
146. Kim YM, Ha YM, Jin YC, Shi LY, Lee YS, Kim HJ, et al. Palmatine from Coptidis rhizoma reduces ischemia-reperfusionmediated acute myocardial injury in the rat. Food Chem Toxicol 2009; 47: 2097-102.
147. Liu J, Ren H, Xu J, Bai R, Yan Q, Huang W, et al. Total synthesis and antihypertensive activity of (+/-)7, 8-dihydroxy-3-methylisochromanone-4. Bioorg Med Chem Lett 2009; 19: 1822-4.
148. Liu JC, Chan P, Chen YJ, Tomlinson B, Hong SH, Cheng JT. The antihypertensive effect of the berberine derivative 6-protoberberine in spontaneously hypertensive rats. Pharmacology 1999; 59: 283-9.
149. Montenegro MF, Neto-Neves EM, Dias-Junior CA, Ceron CS, Castro MM, Gomes VA, et al. Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 293-301.
150. Neto-Neves EM, Montenegro MF, Dias-Junior CA, Spiller F, Kanashiro A, Tanus-Santos JE. Chronic treatment with quercetin does not inhibit angiotensin-converting enzyme in vivo or in vitro. Basic Clin Pharmacol Toxicol 2010; 107: 825-9.
151. Li XQ, Cao W, Li T, et al. Amlodipine inhibits TNF-alpha production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. Int Immunopharmacol 2009; 9: 1032-41.
152. Neri Serneri GG, Boddi M, Modesti PA, et al. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 2004; 94: 1630-7.
153. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R. Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol 2001; 33: 395-403.
154. Ryu S, Shin JS, Cho YW, et al. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. Biol Pharm Bull 2013; 36: 467-74.
155. Pecivova J, Macickova T, Lojek A, et al. In vitro effect of carvedilol on professional phagocytes. Pharmacology 2007; 79: 86-92.
156. Heeba GH, El-Hanafy AA. Nebivolol regulates eNOS and iNOS expressions and alleviates oxidative stress in cerebral ischemia/reperfusion injury in rats. Life Sci 2012; 90: 388-95.
157. de OSMT, Goncalves FM, Martins-Oliveira A, et al. Inducible nitric oxide synthase haplotype associated with migraine and aura. Mol Cell Biochem 2012; 364: 303-8.